Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;46(7):e13057.
doi: 10.1111/pim.13057.

Nonsteroidal Anti-Inflammatory Drugs and Experimental Chagas Disease: An Unsolved Question

Affiliations
Review

Nonsteroidal Anti-Inflammatory Drugs and Experimental Chagas Disease: An Unsolved Question

Scheila Thaís Nicolau et al. Parasite Immunol. 2024 Jul.

Abstract

Chagas disease is a parasitic disease caused by the protozoan Trypanosoma cruzi with an acute, detectable blood parasites phase and a chronic phase, in which the parasitemia is not observable, but cardiac and gastrointestinal consequences are possible. Mice are the principal host used in experimental Chagas disease but reproduce the human infection depending on the animal and parasite strain, besides dose and route of administration. Lipidic mediators are tremendously involved in the pathogenesis of T. cruzi infection, meaning the prostaglandins and thromboxane, which participate in the immunosuppression characteristic of the acute phase. Thus, the eicosanoids inhibition caused by the nonsteroidal anti-inflammatory drugs (NSAIDs) alters the dynamic of the disease in the experimental models, both in vitro and in vivo, which can explain the participation of the different mediators in infection. However, marked differences are founded in the various NSAIDs existing because of the varied routes blocked by the drugs. So, knowing the results in the experimental models of Chagas disease with or without the NSAIDs helps comprehend the pathogenesis of this infection, which still needs a better understanding.

Keywords: NSAIDs; Trypanosoma cruzi infection; immunosuppression; lipidic mediators; parasitemia.

PubMed Disclaimer

References

    1. PAHO (Pan American Health Organization), “Chagas Disease (American Trypanosomiasis),” 2024, https://www.paho.org/en/topics/chagas‐disease.
    1. L. S. Sangenito, M. H. Branquinha, and A. L. S. Santos, “Funding for Chagas Disease: A 10‐Year (2009–2018) Survey,” Tropical Medicine and Infectious Disease 5, no. 2 (2020): 88.
    1. K. M. Bonney, D. J. Luthringer, S. A. Kim, J. Garg, and D. M. Engman, “Pathology and Pathogenesis of Chagas Heart Disease,” Annual Review of Pathology 24, no. 14 (2019): 421–447.
    1. C. W. Cai, J. R. Blase, X. Zhang, C. S. Eickhoff, and D. F. Hoft, “Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruzi,” PLoS Pathogens 12 (2016): e1005902.
    1. H. Rodriguez‐Angulo, J. Marques, I. Mendoza, et al., “Differential Cytokine Profiling in Chagasic Patients According to Their Arrhythmogenic‐Status,” BMC Infectious Diseases 17, no. 221 (2017): 221.

Substances

Grants and funding

LinkOut - more resources